HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Millington, D. S. Search for Related Content PubMed PubMed Citation Articles by Millington, D. S. Related Collections Molecular Diagnostics and Genetics Pediatric Clinical Chemistry Proteomics and Protein Markers Automation and Analytical Techniques

Newborn Screening for Lysosomal Storage Disorders

Duke University Medical Center, Biochemical Genetics Laboratory, 99 Alexander Drive, PO Box 14991, Research Triangle Park, NC 27709, Fax 919-549-0709, E-mail dmilli@duke.edu

The first 20% of the full text of this article appears below.

The concept of screening newborns for inherited metabolic disorders was the brainchild of Robert Guthrie, an upstate New York microbiologist with a passion to prevent the devastating and irreversible neurologic damage sustained by victims of untreated phenylketonuria (PKU). The solution he developed was a simple and inexpensive bacterial inhibition assay for phenylalanine in blood (1). He also invented a unique method of specimen collection, in which peripheral blood was collected from a newborn’s pricked heel onto a special cotton fiber filter-paper known as a "PKU card" or "Guthrie card". After the blood had dried, the specimen was mailed to a laboratory that would identify any child at risk for PKU from a concentration of phenylalanine above an age-matched control limit. Further diagnostic testing was then required to determine whether the disease was present. Treating affected children with a phenylalanine-depleted diet, started within the first month of life, was effective in preventing mental retardation. Unable to persuade the state of New York to conduct newborn screening with the test, Guthrie convinced Massachusetts that the cost of screening the entire population of newborns and treating affected children with the special diet was less than the cost to society of untreated PKU cases. Thus, in 1963 began state-mandated newborn screening for PKU (2). The test was gradually adopted by other states and eventually by countries all over the world.

The success of PKU screening in dried blood spots (DBS), which identifies 200 new cases annually in the United States alone, prompted the addition of tests for other disorders that fit the PKU paradigm. By the mid-1990s, . . . [Full Text of this Article]

The following articles in journals at HighWire Press have cited this article:

				D. S. Millington Rapid and Effective Screening for Lysosomal Storage Disease: How Close Are We? Clin. Chem., October 1, 2008; 54(10): 1592 - 1594. [Full Text] [PDF]